Day One Biopharmaceuticals Acquires Mersana Therapeutics for $25 per Share.

Day One Biopharmaceuticals has successfully closed its acquisition of Mersana Therapeutics, a biopharmaceutical company developing targeted therapies for life-threatening diseases. The acquisition was completed at a price of $25 per share in cash, plus one non-tradable contingent value right to receive up to $30.25 per CVR in cash. The deal expands Day One's focus into adult oncology while maintaining a focus on rare cancers.